Page 40 - Read Online

Wagaskar et al. Mini-invasive Surg 2022;6:14 https://dx.doi.org/10.20517/2574-1225.2021.106 Page 7 of 8

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Dr. Tewari A has served as a site-PI on pharma/industry-sponsored clinical trials from Kite Pharma,
Lumicell Inc, Dendreon, and Oncovir Inc. He has received research funding (grants) to his institution from
DOD, NIH, Axogen, Intuitive Surgical, AMBFF, and other philanthropy. Dr. Tewari A has served as an
unpaid consultant to Roivant Biosciences and advisor to Promaxo. He owns equity in Promaxo. Other
authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Khoo V. Is there another bite of the cherry? Eur Urol 2016;69:13-4. DOI PubMed
2. Evangelista L, Briganti A, Fanti S, et al. New clinical indications for (18)F/(11)C-choline, new tracers for positron emission
tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 2016;70:161-75.
DOI PubMed
3. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a
prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446-53. DOI PubMed
4. Gravis G, Boher JM, Chen YH, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to
benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 2018;73:847-55. DOI PubMed
PMC
5. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer
(STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353-66. DOI PubMed PMC
6. Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J
Radiat Oncol Biol Phys 2004;58:3-10. DOI PubMed
7. Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases.
Eur Urol Oncol 2018;1:46-53. DOI PubMed
8. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic,
and castration-resistant prostate cancer. Eur Urol 2017;71:630-42. DOI PubMed
9. Mathieu R, Korn SM, Bensalah K, Kramer G, Shariat SF. Cytoreductive radical prostatectomy in metastatic prostate cancer: does it
really make sense? World J Urol 2017;35:567-77. DOI PubMed
10. Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J
Clin Oncol 2006;24:2694-6. DOI PubMed
11. Sooriakumaran P, Karnes J, Stief C, et al. A Multi-institutional analysis of perioperative outcomes in 106 men who underwent radical
prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016;69:788-94. DOI PubMed
12. Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone
oligometastases? BJU Int 2018;121:225-31. DOI PubMed
13. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of
the primary tumor? Eur Urol 2014;65:1058-66. DOI PubMed
14. Gandaglia G, Fossati N, Stabile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-
institution series with long-term follow-up. Eur Urol 2017;72:289-92. DOI PubMed
15. Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival
benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol 2015;194:378-85. DOI PubMed PMC
16. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur
Urol 2014;66:602-3. DOI PubMed